Case - II (with domestic benefit): Lets assume that a patent A is filed on 1 Jan 2000, and granted on 1 Jan 2003
FDA approved semaglutide injection (once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol etc), for use in addition to a diet and increased physical activity
GLP-1 therapy helps regulate blood sugar levels by mimicking the natural GLP-1 hormone, which triggers insulin release, reduces glucagon secretion, and slows gastric emptying
It plays an integral role in the synthesis of energy within cells, creating DNA, and supporting bone density
PMID: 31456980
Melanotan II Past research has shown that Melanotan 2 can: Darken skin with sun exposure Affect libido and appetite As Melanotan 2 has a longer half-life than Melanotan I, its effects last longer, It is not available as a prescription medication and is typically less expensive than Melanotan I when purchased as a research chemical
